Fig. 3From: Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort studya Shows the 2-year Kaplan-Meier survival curve for the sarcopenic and non-sarcopenic groups and b shows the 2-year recurrence-free survival curves for these groupsBack to article page